Physician profile
Fred B Rosenberg
NPI 1003817180
$2,564.34
in general payments reported to CMS, 2019-2025
27 companies · $86.08 in 2025
The $86.08 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $143 · 2021: $709 · 2022: $817 · 2023: $38.56 · 2024: $17.09 · 2025: $86.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.29 | 2019-2024 | Rinvoq |
| Janssen Biotech, INC. | $578.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.15 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $197.36 | 2019-2022 | |
| Redhill Biopharma INC. | $112.55 | 2021 | |
| Pfizer INC. | $72.52 | 2020-2022 | |
| Qol Medical, LLC | $51.74 | 2019 | |
| Merck Sharp & Dohme LLC | $43.80 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $40.38 | 2019-2022 | |
| Boston Scientific Corporation | $38.56 | 2019 | |
| Daiichi Sankyo INC. | $37.61 | 2019-2022 | |
| Ucb, INC. | $36.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.64 | 2022 | |
| Celgene Corporation | $28.33 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $20.59 | 2021 | |
| Shionogi INC | $17.59 | 2019 | |
| Genzyme Corporation | $17.31 | 2022 | |
| Ethicon US, LLC | $15.52 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.85 | 2021 | |
| Medtronic, INC. | $12.43 | 2022 | |
| W. L. Gore & Associates, INC. | $11.23 | 2020 | |
| Organon LLC | $7.30 | 2021 | |
| Romark Laboratories, Lc | $6.68 | 2019 | |
| Vivus LLC | $5.55 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,455.94 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.